Isoniazid preventive therapy among HIV infected patients on antiretroviral therapy diagnosed with latent tuberculosis: A retrospective assessment of the outcome in Tanzania

Q3 Medicine

Indian Journal of Tuberculosis Pub Date : 2025-01-01 DOI:10.1016/j.ijtb.2023.07.005

Karol J Marwa , Rachel Maingu

{"title":"Isoniazid preventive therapy among HIV infected patients on antiretroviral therapy diagnosed with latent tuberculosis: A retrospective assessment of the outcome in Tanzania","authors":"Karol J Marwa , Rachel Maingu","doi":"10.1016/j.ijtb.2023.07.005","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>People infected with HIV are at a higher risk up to 20-folds of developing active TB<span> than those not infected with HIV. Isoniazid Preventive Therapy (IPT) is employed in HIV eligible individuals to prevent progression of active tuberculosis (TB) disease. However, there is limited data on the efficacy of IPT in clinical settings in Tanzania and other parts of the world. This study was carried to assess the real-time IPT effectiveness in preventing TB incidences among HIV infected individuals on antiretroviral therapy.</span></div></div><div><h3>Methods</h3><div>A retrospective cohort study was carried employing secondary data of 1000 HIV infected individuals receiving anti-retroviral therapy. TB incidence and associated factors were determined after a four years follow-up.</div></div><div><h3>Results</h3><div>A total of 1000 people were enrolled in the study. The mean age was 44.87 years. The incidence rate was 7.37/1000 person-years (PY) [95% confidence interval (CI) 3.96-13.71]. One percent (1%) of patients developed active tuberculosis within four years of follow up after receiving isoniazid tablets as part of IPT.</div></div><div><h3>Conclusion</h3><div>IPT has a high efficacy in preventing active TB development among HIV infected individuals on ART in clinical settings thus warranting the scale up of IPT services in the country.</div></div>","PeriodicalId":39346,"journal":{"name":"Indian Journal of Tuberculosis","volume":"72 1","pages":"Pages 19-24"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian Journal of Tuberculosis","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0019570723001452","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Background

People infected with HIV are at a higher risk up to 20-folds of developing active TB than those not infected with HIV. Isoniazid Preventive Therapy (IPT) is employed in HIV eligible individuals to prevent progression of active tuberculosis (TB) disease. However, there is limited data on the efficacy of IPT in clinical settings in Tanzania and other parts of the world. This study was carried to assess the real-time IPT effectiveness in preventing TB incidences among HIV infected individuals on antiretroviral therapy.

Methods

A retrospective cohort study was carried employing secondary data of 1000 HIV infected individuals receiving anti-retroviral therapy. TB incidence and associated factors were determined after a four years follow-up.

Results

A total of 1000 people were enrolled in the study. The mean age was 44.87 years. The incidence rate was 7.37/1000 person-years (PY) [95% confidence interval (CI) 3.96-13.71]. One percent (1%) of patients developed active tuberculosis within four years of follow up after receiving isoniazid tablets as part of IPT.

Conclusion

IPT has a high efficacy in preventing active TB development among HIV infected individuals on ART in clinical settings thus warranting the scale up of IPT services in the country.

查看原文本刊更多论文

在被诊断为潜伏性结核病的HIV感染患者中进行异烟肼预防性治疗的抗逆转录病毒治疗：坦桑尼亚结果的回顾性评估

背景：与未感染艾滋病毒的人相比，感染艾滋病毒的人患活动性结核病的风险高达20倍。异烟肼预防治疗（IPT）用于艾滋病毒感染者，以预防活动性结核病（TB）疾病的进展。然而，关于IPT在坦桑尼亚和世界其他地区临床环境中的疗效的数据有限。本研究旨在评估实时IPT在抗逆转录病毒治疗的HIV感染者中预防结核病发病率的有效性。方法：采用辅助资料对1000例接受抗逆转录病毒治疗的HIV感染者进行回顾性队列研究。结核发病率及相关因素在4年随访后确定。结果：共有1000人参加了这项研究。平均年龄44.87岁。发病率为7.37/1000人年（PY）[95%可信区间（CI） 3.96 ~ 13.71]。1%的患者在接受异烟肼片作为IPT的一部分后的四年随访中出现活动性肺结核。结论：在临床环境中，抗逆转录病毒疗法在预防接受抗逆转录病毒治疗的艾滋病毒感染者的活动性结核病发展方面具有很高的疗效，因此有必要在该国扩大抗逆转录病毒疗法的服务。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Indian Journal of Tuberculosis Medicine-Infectious Diseases

CiteScore

2.80

自引率

0.00%

发文量

103

期刊介绍： Indian Journal of Tuberculosis (IJTB) is an international peer-reviewed journal devoted to the specialty of tuberculosis and lung diseases and is published quarterly. IJTB publishes research on clinical, epidemiological, public health and social aspects of tuberculosis. The journal accepts original research articles, viewpoints, review articles, success stories, interesting case series and case reports on patients suffering from pulmonary, extra-pulmonary tuberculosis as well as other respiratory diseases, Radiology Forum, Short Communications, Book Reviews, abstracts, letters to the editor, editorials on topics of current interest etc. The articles published in IJTB are a key source of information on research in tuberculosis. The journal is indexed in Medline